Project Application

• Scope: Regeneration of cells/tissue/organs to restore or establish functionality and health

The Wyss Zurich Translational Center (Wyss Zurich) does not support research activities; Wyss Zurich supports the advancements of therapies towards the clinic, the development of technologies towards the market as well as the clinic with the following activities:

• Preclinical studies under GLP conditions
• Production of clinical grade material under GMP certified conditions
• Production of medical device technologies under ISO regulation
• First-in-man studies and early phases of clinical trials

• PoC of the regenerative technology must have been demonstrated in at least one relevant in-vivo model.

• Projects must be supported by an innovative research background and scientific excellence.
• Projects need to address an unmet need and face a valley of death concerning clinical translation / technology transfer.
• The team must have a convincing business model and sound go-to-market considerations.
• The team should act and be ready to grow as entrepreneurs with plans to continue the project beyond the Wyss Zurich Translational Center period.

• Projects must demonstrate high market need and industry interest and the potential for scaling to an important business.
• The product must be economically feasible with a preliminary business plan.
• Products and technology need preliminary plans for scalable production.

• Projects must have IP potential to provide opportunities for sustainable business and growth.
• Relevant IP needs to be protected (e.g., patent application, software source code).
• Candidates should be able to provide an overview on the competitive landscape to determine whether the development and commercialization of the technology/therapy is possible without infringing valid intellectual property rights of others (FTO).
• Ownership of underlying IP should be with ETH Zurich and/or UZH.
• If IP is partly/fully owned by a third party, a commercialization agreement is required to ensure that projects have unrestricted/exclusive access to the underlying IP.

• A team leader(s) must be identified prior to the start of the Wyss Zurich project. This/these person/persons should demonstrate full commitment to pursue the project beyond the Wyss Zurich Translational Center period, to become an entrepreneur(s). The team leader must not be a faculty member.
• Faculty members who are strongly involved with the project may be appointed as Faculty Mentors for the duration of the Wyss Zurich project.
• Required key positions should be identified and ideally already filled.

• Robotics Scope: Development of devices and technologies in the field of Robotics and intelligent systems
• Medical Devices / Bionics Scope: Development of medical devices. Preferably, hybrid technologies from the fields of Regenerative Medicine and Robotics

The Wyss Zurich Translational Center (Wyss Zurich) does not support research activities; Wyss Zurich supports the advancements of therapies towards the clinic, the development of technologies towards the market as well as the clinic with the following activities:

Robotics:

• Elaboration of technical specifications (market-driven)
• Design for production and optimization
• Production of prototypes
• Testing and validation up to early beta-testers
• Product or components should be ready for industrial production at the end of the Wyss Zurich Translational Center period.

Medical Technology / Bionics:

• Elaboration of technical specifications
• Design for production and optimization
• Production of medical device/bionic technologies for validation according to applicable standards
• Products should move to clinical validation and/or obtained Swiss or EU market authorization at the end of the Wyss Zurich Translational Center period.

• A functioning prototype (software and/or hardware) of a technology must have been developed.

• Projects must be supported by an innovative research background and scientific excellence.
• Projects need to address an unmet need and face a valley of death concerning clinical translation / technology transfer.
• The team must have a convincing business model and sound go-to-market considerations.
• The team should act and be ready to grow as entrepreneurs with plans to continue the project beyond the Wyss Zurich Translational Center period.

• Projects must demonstrate high market need and industry interest and the potential for scaling to an important business.
• The product must be economically feasible with a preliminary business plan.
• Products and technology need preliminary plans for scalable production.

• Projects must have IP potential to provide opportunities for sustainable business and growth.
• Relevant IP needs to be protected (e.g., patent application, software source code).
• Candidates should be able to provide an overview on the competitive landscape to determine whether the development and commercialization of the technology/therapy is possible without infringing valid intellectual property rights of others (FTO).
• Ownership of underlying IP should be with ETH Zurich and/or UZH.
• If IP is partly/fully owned by a third party, a commercialization agreement is required to ensure that projects have unrestricted/exclusive access to the underlying IP.

• A team leader(s) must be identified prior to the start of the Wyss Zurich project. This/these person/persons should demonstrate full commitment to pursue the project beyond the Wyss Zurich Translational Center period, to become an entrepreneur(s). The team leader must not be a faculty member.
• Faculty members who are strongly involved with the project may be appointed as Faculty Mentors for the duration of the Wyss Zurich project.
• Required key positions should be identified and ideally already filled.